Abstract
Aminosalycylates (5-ASA) are still the drugs of choice both for mild-to-moderate outbreaks of ulcerative colitis and to maintain long-term remission. The efficacy of these drugs has been widely demonstrated in placebo-controlled trials. However, when administered orally, their pharmacological characteristics hamper the desired therapeutic effect. Currently, efficiency can be optimized by exclusive or combined rectal administration. The present article reviews the available data on the efficacy of galenic preparations of 5-ASA and discusses the potential advantages of galenic forms of 5-ASA coated with a novel multi-matrix delivery system.
Keywords:
Aminosalicilatos; Aminosalycylates; Colitis ulcerosa; Mesalazina; Mesalazine; Multi-matrix; Multimatrix; Ulcerative colitis.
Copyright © 2011 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Administration, Oral
-
Administration, Rectal
-
Aminosalicylic Acids / administration & dosage
-
Aminosalicylic Acids / adverse effects
-
Aminosalicylic Acids / pharmacokinetics
-
Aminosalicylic Acids / therapeutic use*
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Colitis, Ulcerative / drug therapy*
-
Drug Administration Schedule
-
Drug Compounding
-
Humans
-
Mesalamine / administration & dosage
-
Mesalamine / adverse effects
-
Mesalamine / pharmacokinetics
-
Mesalamine / therapeutic use
-
Randomized Controlled Trials as Topic
-
Tablets, Enteric-Coated
Substances
-
Aminosalicylic Acids
-
Anti-Inflammatory Agents, Non-Steroidal
-
Tablets, Enteric-Coated
-
Mesalamine